Overview

Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with GlaxoSmithKline Purinethol® (mercaptopurine) 50-mg scored tablets following a single 50 mg oral dose administered in the fasted state.
Phase:
N/A
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
6-Mercaptopurine
Mercaptopurine